Wolverine Blend (BPC-157 + TB-500) 10mg — Vial Spec, Reconstitution Math & COA

Overview of the 10mg Wolverine Blend Specification

In experimental biology and cellular modeling, combining synthetic peptides with complementary signaling cascades requires rigorous mass balance and purity verification. The 10mg Wolverine Blend research vial contains a total mass of 10mg lyophilized active substance, composed of an exact 1:1 molar/mass ratio of 5mg Pentadecapeptide BPC-157 and 5mg Thymosin Beta-4 fragment (TB-500). This precise co-formulation is engineered for in vitro assays and preclinical animal models investigating connective tissue repair, angiogenesis, and cell migration dynamics.

Principal investigators and laboratory managers routinely select the 10mg total vial specification when conducting medium-to-high throughput assay series or extended animal model protocols. Sourcing a combined 10mg vial streamlines stock solution preparation, minimizes potential errors during serial pipetting, and ensures consistent stoichiometry across cell culture plates. By maintaining high-purity single-vial delivery, research teams reduce batch-to-batch variability while evaluating dual-peptide signaling mechanisms.

PX1 Research Catalog Availability & Formulation Context

PX1 Research manufactures and supplies this dual-peptide combination under strict quality control standards. In our standard research catalog, this specific 10mg co-lyophilized ratio is stocked as our flagship dual-action regenerative research compound, available directly via our 5mg BPC-157 / 5mg TB-500 Wolverine Blend product page. Every production lot manufactured in our domestic GMP-compliant facility undergoes identical analytical testing regardless of fill mass.

For investigators evaluating broader research designs or requiring individual monopeptide controls alongside dual-blend groups, our complete inventory can be inspected across our all research peptides catalog. Researchers requiring higher vial yields or custom fill sizes for automated high-throughput assay platforms can coordinate directly with our team via our wholesale peptide program to set up custom lot manufacturing with dedicated analytical validation.

Synergistic Preclinical Mechanisms: Angiogenesis and Actin Cytoskeletal Dynamics

Understanding the biochemical rationale behind combining BPC-157 and TB-500 requires examining their distinct yet overlapping molecular targets in preclinical literature. BPC-157 (Body Protection Compound 157) is a 15-amino acid peptide derived from human gastric juice sequence, studied extensively in animal models for its modulation of the focal adhesion kinase (FAK) and paxillin pathway, upregulation of vascular endothelial growth factor (VEGF) expression, and nitric oxide (NO) pathway activation. In contrast, TB-500 (a synthetic derivative of the active domain of Thymosin Beta-4) functions primarily as a G-actin sequestering protein, promoting cell motility, actin polymerization, and tissue remodeling.

In vitro models demonstrate that when endothelial cells or fibroblast cultures are exposed to both compounds, cell migration rates and capillary-like tube formation exceed baseline levels observed with single-agent controls. Preclinical rodent models investigating tendon-to-bone healing and skeletal muscle injury suggest that BPC-157 accelerates early stage fibroblast recruitment and collagen type I synthesis, while TB-500 mobilizes progenitor cells and reorganizes the actin cytoskeleton to optimize cellular architecture. Investigating these dual pathways in tandem allows laboratories to explore complex tissue repair dynamics that cannot be fully captured by monopeptides alone.

Reconstitution Math for 10mg Vials (1mL, 2mL, and 3mL Diluent Volumes)

Accurate reconstitution of a 10mg total peptide vial (5mg BPC-157 + 5mg TB-500) requires precise volumetric calculations to achieve target working concentrations. Because the total active mass is 10mg (10,000 micrograms), calculating concentration based on total peptide mass or individual component mass is straightforward. Researchers can verify their math using our interactive peptide reconstitution calculator. Below are the standard volumetric dilutions utilized in laboratory environments:

1.0 mL Diluent Addition: Adding 1.0 mL of sterile bacteriostatic water yields a total concentration of 10.0 mg/mL (10.0 mcg/µL total peptide). Within this solution, each 0.1 mL (100 µL or 10 units on a standard U-100 syringe volumetric scale) contains 1.0 mg of combined peptide (0.5 mg BPC-157 + 0.5 mg TB-500). This high concentration is ideal for low-volume micro-injection setups in small rodent models or microfluidic assays.

2.0 mL Diluent Addition: Adding 2.0 mL of bacteriostatic water yields a total concentration of 5.0 mg/mL (5.0 mcg/µL total peptide). In this setup, each 0.1 mL volumetric draft contains 0.5 mg of combined peptide (0.25 mg BPC-157 + 0.25 mg TB-500). This dilution provides optimal pipetting precision for cell culture dosing where intermediate stock solutions are required.

3.0 mL Diluent Addition: Adding 3.0 mL of diluent produces a total concentration of approximately 3.33 mg/mL (3.33 mcg/µL total peptide). A 0.1 mL aliquot delivers approximately 0.333 mg of combined peptide (0.167 mg BPC-157 + 0.167 mg TB-500). This lower concentration is frequently chosen when conducting delicate multi-well plate assays where liquid handling equipment requires larger pipetting volumes to maintain sub-percentage precision.

Aliquot Planning and Degradation Prevention

Repeated freeze-thaw cycles present a significant threat to peptide secondary structure and biological activity. Upon reconstituting a 10mg Wolverine Blend vial, laboratory technicians should immediately divide the stock solution into single-use microcentrifuge aliquots using sterile, polypropylene tubes. Working with single-use aliquots prevents head-space air oxidation and eliminates the thermal stress associated with multiple warming and re-cooling cycles.

When planning aliquots, ensure that the chosen vessel material is low-binding polypropylene to prevent non-specific peptide adsorption to container walls. Aliquots designated for immediate assay use over a 24- to 72-hour window should be stored at 2°C to 8°C. Portions reserved for long-term experimental protocols across several weeks or months should be flash-frozen in liquid nitrogen or ultra-low freezers (-20°C to -80°C) and thawed only once immediately prior to assay administration.

Storage Protocols for Lyophilized and Reconstituted Vials

The physical stability of lyophilized peptide cakes is highly dependent on ambient temperature, humidity, and light exposure. In their un-reconstituted, lyophilized state, PX1 Research 10mg Wolverine Blend vials should be stored at -20°C for long-term stability up to 24 months. If short-term storage (under 30 days) is required before experimental setup, storage at standard refrigeration (2°C to 8°C) in a dry, dark environment is acceptable.

Once reconstituted with bacteriostatic water containing 0.9% benzyl alcohol, the aqueous solution remains stable at 2°C to 8°C for up to 28 days. Benzyl alcohol acts as a bacteriostatic preservative, inhibiting microbial proliferation in multi-dose lab vials. Reconstituted solutions prepared with unpreserved sterile 0.9% sodium chloride or sterile water must be used within 24 hours. Lyophilized and reconstituted vials must always be protected from direct light exposure and high-frequency mechanical agitation, which can induce protein aggregation.

Analytical Verification: Lot-Matched HPLC, Mass Spectrometry, and COAs

To guarantee experimental reproducibility and baseline purity, every production batch of Wolverine Blend from PX1 Research undergoes rigorous, independent analytical testing. We issue a lot-matched Certificate of Analysis (COA) for every batch, confirming chemical identity and purity via High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). Researchers can directly access and download raw analytical documentation for their specific lot through our public COA verification portal.

Our dual-peptide testing protocols verify both individual peptide peaks on the HPLC chromatogram, ensuring that BPC-157 and TB-500 achieve an individual purity rating of ≥98.0%. Furthermore, mass spectrometry confirms the exact molecular weights—1419.5 Da for BPC-157 and 4963.5 Da for TB-500—without secondary fragment degradation. Every lot is also subjected to kinetic chromogenic LAL assays to ensure endotoxin levels remain strictly below <0.01 EU/mg, preventing confounding inflammatory responses in sensitive cell lines or animal tissues.

Comparative Analysis of Tissue Repair Research Peptides

Selecting the appropriate peptide tool depends entirely on the specific signaling pathway or cell type under investigation. While the Wolverine Blend provides dual action targeting both FAK/VEGF and actin monomer sequestration, other research compounds offer distinct mechanisms for cellular repair studies. Exploring related compounds within our broad research library assists investigators in building comprehensive comparative experimental designs.

For example, researchers exploring anti-inflammatory pathways or dermal extracellular matrix remodeling often compare BPC-157/TB-500 against KPV peptide or GHK-Cu copper peptide. KPV targets NF-κB inflammatory signaling cascades in epithelial cells, whereas GHK-Cu modulates gene expression related to collagen synthesis and metalloproteinase balance. Furthermore, laboratories requiring isolated single-pathway controls often run standalone assays using individual BPC-157 research vials or isolated TB-500 research vials to isolate baseline responses against the synergistic Wolverine Blend model.

Selecting Between 10mg Blends vs. Standalone Monopeptides

When designing a research study, investigators must evaluate whether a pre-formulated 10mg blend or separate monopeptide vials best serve their laboratory requirements. The 10mg Wolverine Blend offers significant practical advantages: it reduces solvent consumption, lowers plastic consumable waste, decreases syringe pump setup time, and guarantees a consistent 1:1 mass ratio between BPC-157 and TB-500 in every volumetric micro-dose.

Conversely, if an experimental protocol requires variable dosage ratios—such as escalating BPC-157 concentrations while holding TB-500 constant—sourcing standalone monopeptide vials is necessary. Laboratories performing broad matrix screening protocols often maintain stock of both individual BPC-157 and TB-500 alongside pre-mixed 10mg Wolverine Blend vials to accommodate both fixed-ratio assay runs and variable-ratio control groups.

Laboratory Safety, Handling SOPs, and Regulatory Status

All compounds supplied by PX1 Research, including the 10mg Wolverine Blend, are strictly designated for laboratory research use only by qualified scientific personnel. They are not intended for human or veterinary use, clinical trials, therapeutic administration, or agricultural application. Standard Operating Procedures (SOPs) for handling synthetic peptides must be followed at all times.

Personnel handling lyophilized peptide powders should wear appropriate personal protective equipment (PPE), including nitrated lab gloves, lab coats, and safety eyewear, inside a certified laminar flow hood or biosafety cabinet. Spills should be neutralized immediately in accordance with institutional biosafety guidelines. Proper documentation of stock solution generation, storage temperatures, and lot numbers must be maintained to comply with institutional research standards.